TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28293345

Group type: EXPERIMENTAL
Intervention: Male involvement intervention (MI)
Number of subjects: 462

Group type: COMPARATOR
Intervention: No male involvement (control group)
Number of subjects: 462
Study: 24589291

Group type: EXPERIMENTAL
Intervention: Tailored, multi-component implementation intervention including an implementation seminar, website, and email reminders
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Implementation seminar
Number of subjects: 448
Study: 22340459

Group type: EXPERIMENTAL
Intervention: Magnetic navigation system guidance (MNS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional technique (CMT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (MNS and CMT)
Number of subjects: 40
Study: 20147680

Group type: EXPERIMENTAL
Intervention: Peer-led lifestyle intervention group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 18855510

Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paternal depressive symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child noncompliance at age 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child internalizing behaviors at age 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child externalizing behaviors at age 4
Number of subjects: 0
Study: 14709944

Group type: EXPERIMENTAL
Intervention: Atomoxetine (discontinued after 9 to 10 weeks of continuous therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (continuing treatment)
Number of subjects: 0
Study: 11159255

Group type: EXPERIMENTAL
Intervention: Standardized montage (Montage I)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Montage II
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Montage III
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Montage IV
Number of subjects: 72
Study: 9270562

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFN beta-1a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7934135

Group type: EXPERIMENTAL
Intervention: rhEPO 400 U/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhEPO during extension phase
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline erythropoietin level < 50 mU/ml
Number of subjects: 20
Study: 3207009

Group type: EXPERIMENTAL
Intervention: Oral antibiotics plus acute myringotomy (group B)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Oral antibiotics (group A)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 79
Study: 29957104

Group type: EXPERIMENTAL
Intervention: Pomegranate Juice (PJ)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 28817201

Group type: COMPARATOR
Intervention: Biologics for rheumatoid arthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different doses of biologics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous measures of ACR subcomponents
Number of subjects: 0
Study: 26005963

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg bid)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 23778198

Group type: EXPERIMENTAL
Intervention: Multicomponent cognitive behavioral group intervention (8 weekly sessions + 1 booster session)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 540
Study: 21418923

Group type: EXPERIMENTAL
Intervention: r‐bFGF eye drops, four times a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: r‐bFGF eye-gel, four times a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drops (Control)
Number of subjects: 60
Study: 18482663

Group type: EXPERIMENTAL
Intervention: Low-flow-mediated constriction (L-FMC)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 196
Study: 16520567

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse with gingival massage toothbrushing for 2 weeks (4 times per day, 3 minutes per session)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group received toothbrushing education on gingival massage toothbrushing without essential oil mouthrinse
Number of subjects: 61
Study: 14746674

Group type: EXPERIMENTAL
Intervention: Health education intervention for one year
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 180
Study: 11020033

Group type: COMPARATOR
Intervention: Aerosolized standard heparin (1.000 U/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aerosolized LMWH (Enoksaparin, Clexane, 0.8 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9244815

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid from borage seed oil (360 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Corn seed oil (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid from borage seed oil
Number of subjects: 24
Study: 1302545

Group type: EXPERIMENTAL
Intervention: Radiotherapy + 10% Brucea javanica emulsion
Number of subjects: 68

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 68
Study: 3937220

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (20-40 donors, n = 6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stored plasma (250-300 ml, n = 5)
Number of subjects: 11
Study: 30511096

Group type: EXPERIMENTAL
Intervention: Sensor-assisted TKA (group S)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manually balanced TKA (group M)
Number of subjects: 100
Study: 28823411

Group type: EXPERIMENTAL
Intervention: Female concordant visits
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Female physicians
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Male physicians
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Gender concordance
Number of subjects: 103
Study: 27829392

Group type: EXPERIMENTAL
Intervention: Illness Management & Recovery (IMR) program
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IMR Fidelity Scale
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Trainers' education and supervision
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dropout rate
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Duration of IMR program
Number of subjects: 81
Study: 24691459

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nefopam + Fentanyl
Number of subjects: 92
Study: 22520143

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study: 21413596

Group type: EXPERIMENTAL
Intervention: Total Lymphocyte Count (TLC)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Hemoglobin
Number of subjects: 1078
Study: 17277790

Group type: EXPERIMENTAL
Intervention: Cryotherapy during MTX administration
Number of subjects: 130

Group type: COMPARATOR
Intervention: No cryotherapy during MTX administration (Control)
Number of subjects: 130
Study: 15204668

Group type: EXPERIMENTAL
Intervention: Integrated treatment for co-occurring conditions
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Training counseling staff to handle psychotic symptoms
Number of subjects: 1016
Study: 11593354

Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fat (Trial I)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (Trial II)
Number of subjects: 71
Study: 9520072

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of amyloid beta-peptide (Abeta) in Alzheimer's disease patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of amyloid beta-peptide (Abeta) in major depression patients
Number of subjects: 0
Study: 8036961

Group type: EXPERIMENTAL
Intervention: Experimental group with mastery criteria and contingent reinforcement for diet, exercise, weight loss, and parenting skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with behavior-change strategies and noncontingent reinforcement
Number of subjects: 0
Study: 2658042

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 59
Study: 31799861

Group type: EXPERIMENTAL
Intervention: ERAS protocol with postoperative intravenous Flubiprofen Axetil or analgesia pump
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 55
Study: 29626176

Group type: EXPERIMENTAL
Intervention: Preventive ceftriaxone
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Standard stroke unit care (control)
Number of subjects: 2550
Study: 27861190

Group type: EXPERIMENTAL
Intervention: Dual acid-etched (DAE) implants
Number of subjects: 14

Group type: COMPARATOR
Intervention: Machined (MA) implants
Number of subjects: 14
Study: 25741159

Group type: EXPERIMENTAL
Intervention: Tissue selecting therapy stapler (TST)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy (M‐M)
Number of subjects: 480
Study: 24474353

Group type: EXPERIMENTAL
Intervention: CanalBrush for 20 s at 450 rpm
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group A (10 mL 17% EDTA and 10 mL 2.5% NaOCl)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group C (CanalBrush and 10 mL NaOCl)
Number of subjects: 44
Study: 21036457

Group type: EXPERIMENTAL
Intervention: Video coaching via cellular phones
Number of subjects: 78

Group type: COMPARATOR
Intervention: Audio-assisted instructions
Number of subjects: 78
Study: 18469250

Group type: EXPERIMENTAL
Intervention: Prior diet standardization (D, n = 32)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No prior diet standardization (ND, n = 23)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Prior diet standardization (D)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No prior diet standardization (ND)
Number of subjects: 55
Study: 17144556

Group type: EXPERIMENTAL
Intervention: Low-intensity laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0
Study: 12680517

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four external cooling strategies
Number of subjects: 0
Study: 15798126

Group type: EXPERIMENTAL
Intervention: High-intensity group (7 visits and full set of resources)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Low-intensity group (1 visit and limited resources)
Number of subjects: 274
Study: 10340280

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HRT (non-randomised arm)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: No treatment (non-randomised arm, Control)
Number of subjects: 2016
Study: 7867052

Group type: EXPERIMENTAL
Intervention: Sugar restriction (test group, n = 12)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No dietary advice (control group, n = 8)
Number of subjects: 20
Study: 1959402

Group type: EXPERIMENTAL
Intervention: Albuterol (5 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Isoproterenol (5 mg)
Number of subjects: 180
Study: 6752874

Group type: EXPERIMENTAL
Intervention: pirprofen 800 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: ketoprofen 300 mg/day
Number of subjects: 40
Study: 27884550

Group type: EXPERIMENTAL
Intervention: High-carbohydrate/high-glycemic-index (HGI) diet
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: High-carbohydrate/low-glycemic-index (LGI) diet
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Lower-carbohydrate/high-monounsaturated-fat (LC) diet
Number of subjects: 162

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 162
Study: 25185470

Group type: EXPERIMENTAL
Intervention: Nonoperative management (NOM) with serial clinical examination alone
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Nonoperative management (NOM) with abdominal CT scanning
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Nonoperative management (NOM) overall
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Immediate laparotomy
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Delayed laparotomy after NOM
Number of subjects: 1106
Study: 24022237

Group type: EXPERIMENTAL
Intervention: Active oromucosal nicotine spray (1 or 2 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo oromucosal nicotine spray
Number of subjects: 32
Study: 22707253

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18563517

Group type: EXPERIMENTAL
Intervention: High-dose L-alanyl-L-glutamine dipeptide [0.5 g/(kg day) glutamine]
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group with isonitrogeneous, isocaloric, isovolemic nutritional solution
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 78
Study: 17330781

Group type: EXPERIMENTAL
Intervention: Paired samples collected before treatment and at recurrence of parasitemia.
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Recurrent infections in Thai and Burmese patients.
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Recurrent infections in Indian patients.
Number of subjects: 149
Study: 15496604

Group type: EXPERIMENTAL
Intervention: Milk-based formula with 72 mg ribonucleotides/L (FN)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Human milk-fed (HMF)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Milk-based formula without ribonucleotides (F)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Milk-based formula with ribonucleotides (FN)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: All groups (FN, F, HMF)
Number of subjects: 477
Study: 11439411

Group type: EXPERIMENTAL
Intervention: 6-week circuit weight training program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no weight training)
Number of subjects: 39
Study: 9737454

Group type: EXPERIMENTAL
Intervention: Aspirin and Warfarin (WAR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 56
Study: 7520395

Group type: EXPERIMENTAL
Intervention: Sperm treated with pentoxifylline and 2-deoxyadenosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sperm not treated with pentoxifylline and 2-deoxyadenosine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment and control groups
Number of subjects: 0
Study: 2902545

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry
Number of subjects: 22

Group type: COMPARATOR
Intervention: Topical beta-blocker treatment
Number of subjects: 22
Study: 30611727

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active Control (AC)
Number of subjects: 44
Study: 28685397

Group type: EXPERIMENTAL
Intervention: 3QD regimen (once daily: ombitasvir/paritaprevir/ritonavir and dasabuvir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3‐DAA regimen (twice daily: ombitasvir/paritaprevir/ritonavir and dasabuvir)
Number of subjects: 0
Study: 25688779

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (0.5mg/kg per 12 hours for 5 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 120
Study: 22658379

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (SMART study)
Number of subjects: 113
Study: 21330621

Group type: EXPERIMENTAL
Intervention: Maximum isometric ankle dorsiflexion contractions (1 second duration)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NIRS data acquisition (subset of 7 subjects)
Number of subjects: 11
Study: 20395851

Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 660
Study: 17657475

Group type: EXPERIMENTAL
Intervention: Surgical treatment with decompression and various spondylodeses (n=13)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conservative treatment (n=6)
Number of subjects: 19
Study: 15870625

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (21 g x d(-1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12215281

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) for 6 courses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual drugs used in the clinic for 60 days
Number of subjects: 60
Study: 11776765

Group type: EXPERIMENTAL
Intervention: Carboplatin (100 mg, d 1-5) and 5-fluorouracil (500 mg, d 1-5) plus radiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 80
Study: 8574715

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Intravenous cefuroxime
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cefuroxime protocol
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin protocol
Number of subjects: 209
Study: 2186951

Group type: COMPARATOR
Intervention: arbaprostil 10 micrograms
Number of subjects: 658

Group type: COMPARATOR
Intervention: arbaprostil 25 micrograms
Number of subjects: 658

Group type: COMPARATOR
Intervention: arbaprostil 50 micrograms
Number of subjects: 658
Study: 531541

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (daily dosage)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (alternate-day regimen)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Observation without therapy (Control)
Number of subjects: 39
Study: 31812890

Group type: EXPERIMENTAL
Intervention: Alectinib 300 mg twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 207
Study: 28528354

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Fixed Resistance Training (FRT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 109
Study: 26389945

Group type: EXPERIMENTAL
Intervention: Dairy intake
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Meat intake
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fish and shellfish intake
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Egg intake
Number of subjects: 600
Study: 24353023

Group type: EXPERIMENTAL
Intervention: Tapentadol ER tablets (50, 100, 150, 200, or 250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapentadol ER tablets (250 mg) administered every 12 hours (five doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapentadol ER tablets (250 mg) with a high-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tapentadol ER tablets (single dose)
Number of subjects: 0
Study: 21464293

Group type: EXPERIMENTAL
Intervention: Human recombinant leptin (metreleptin) in replacement doses over 36 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human recombinant leptin (metreleptin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19011727

Group type: EXPERIMENTAL
Intervention: Exercise program (calisthenics, body balance training, muscle power training, walking ability training) 3 days/week for 5 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 68
Study: 17084196

Group type: EXPERIMENTAL
Intervention: Craniotomy and early hematoma evacuation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Best medical management (control)
Number of subjects: 108
Study: 14702269

Group type: EXPERIMENTAL
Intervention: Continued perphenazine treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 11579988

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exposure therapy (E)
Number of subjects: 16
Study: 9360528

Group type: EXPERIMENTAL
Intervention: Fasting (56 h of total caloric deprivation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) infusions at a dose of 34-46 mg HC/24 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) infusions
Number of subjects: 8
Study: 8432442

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 20 mg daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily (tapering to 10 or 20 mg)
Number of subjects: 205
Study: 3665384

Group type: EXPERIMENTAL
Intervention: Syringe-pump system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minibottle system
Number of subjects: 30
Study: 30222050

Group type: EXPERIMENTAL
Intervention: Cognitive training based on motor imagery (MI) and action observation (AO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Basic surgical skill group (short 2-day laparoscopic course)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (neutral activity)
Number of subjects: 28
Study: 27022118

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily; n = 172)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5 to 6; n = 171)
Number of subjects: 343
Study: 24526744

Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops (twice daily for 3 days)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Tobramycin 0.3% eye drops (every 2 h for 2 days, then four times daily for 5 days)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops
Number of subjects: 286

Group type: COMPARATOR
Intervention: Tobramycin 0.3% eye drops
Number of subjects: 286
Study: 22285891

Group type: EXPERIMENTAL
Intervention: Choice condition (n=44)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No-choice condition (n=40)
Number of subjects: 84
Study: 19783377

Group type: EXPERIMENTAL
Intervention: PCV chemotherapy plus radiation therapy (PCV + RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV + RT
Number of subjects: 0
Study: 18297481

Group type: EXPERIMENTAL
Intervention: Comprehensive exercise routine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supervised walking
Number of subjects: 45

Group type: COMPARATOR
Intervention: Social conversation
Number of subjects: 45